Cluster Subanalysis of Patients With Severe Asthma Who Responded to Omalizumab

Dávila I 1,2, Campo P 3, Cimbollek S 4, Almonacid Sánchez C 5, Quirce S 6,7, Moreira A 8, Ramirez A 8, Soto Campos G 9
1 Allergy Service, University Hospital of Salamanca and Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain
2 Biomedical and Diagnosis Science Department, Salamanca University School of Medicine, Salamanca, Spain
3 Allergy Unit, IBIMA-Regional University Hospital of Málaga, Málaga, Spain
4 Department of Allergy, Hospital Universitario Virgen del Rocio, Sevilla, Spain
5 Department of Respiratory Medicine, Ramón y Cajal Hospital, IRYCIS, Alcala de Henares University, Madrid, Spain
6 Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
7 CIBER de Enfermedades Respiratorias, CIBERES, Madrid, Spain
8 Novartis Farmacéutica, Barcelona, Spain
9 Pneumology and Allergy Unit, Hospital Universitario de Jerez, Cádiz, Spain

doi: 10.18176/jiaci.0731

Key words: IgE. Asthma. Allergens and epitopes. Eosinophils.

Palabras clave: IgE. Asma. Alérgenos y epitopos. Eosinófilos.

Asthma is a heterogeneous disease that manifests with variations in signs and symptoms, age of onset, triggers, disease progression, pulmonary function, and airway inflammation [1]. Recently, significant efforts have been made to phenotype asthma, with the objective of identifying patients who are responsive to specific therapies [2]. The different methods used to phenotype asthma have generated bias [3]. In this sense, cluster approaches are one of the most frequently used unbiased techniques [4]. They are generally based on cohorts of patients analyzed using a cluster methodology, which gives rise to various phenotypes [5-7]. Here, we used an innovative contrasting approach, namely, a real-world study in which we selected patients with an excellent response to omalizumab (hyperresponders) and performed a cluster analysis to identify responder phenotypes.

FENOMA was a multicenter, retrospective observational real-world study of patients aged ≥18 years with severe asthma who achieved complete asthma control according to the Spanish Guideline on Asthma Management (GEMA) [8] after 1 year of treatment with omalizumab. The design of this study has been published elsewhere [9]. Asthma control was considered to be complete if the patient had no diurnal asthma symptoms or asthma symptoms ≤2 d/wk, no nocturnal symptoms, no need for rescue medication ≤2 d/wk, normal pulmonary function, no activity limitation, and no severe asthma exacerbations during this period. These patients were considered hyperresponders. Patients had been retrospectively assigned by their physician to a pre-established phenotype [5,6,10] before receiving treatment with omalizumab. However, the definition of severe asthma phenotypes has evolved since the study was designed (2014), with current phenotypes being more concise and less numerous. The older definitions in the FENOMA study meant a large degree of overlap between phenotypes, thus making it difficult for physicians to select the phenotype (as required by the design of the study) [9]. Therefore, in order to obtain an unsupervised description of responders to omalizumab, we performed a post hoc cluster analysis to find phenotypes among patients who had achieved complete control of the disease during the first year of treatment with omalizumab and identify them in the real-world clinical setting. The variables used to determine clusters and Materials and Methods are described in the Table and Supplementary Information, respectively.

Four clusters were identified in 256 patients, namely, C1, C2, C3, and C4, which included 141 (55.1%), 96 (37.5%), 12 (4.7%), and 7 patients (2.7%), respectively. The cluster

<table>
<thead>
<tr>
<th>Variables</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
</tr>
<tr>
<td>Forced expiratory volume in 1 second</td>
</tr>
<tr>
<td>Sex</td>
</tr>
<tr>
<td>Blood eosinophil count</td>
</tr>
<tr>
<td>Smoking history</td>
</tr>
<tr>
<td>Number of nonsevere asthma episodes</td>
</tr>
<tr>
<td>Comorbidities*</td>
</tr>
<tr>
<td>Number of visits to the emergency room due to asthma exacerbation</td>
</tr>
<tr>
<td>Time from asthma diagnosis to severe asthma diagnosis</td>
</tr>
<tr>
<td>Admissions to ICU due to asthma exacerbation</td>
</tr>
<tr>
<td>Duration of severe asthma until therapy</td>
</tr>
<tr>
<td>Dose of inhaled corticosteroids</td>
</tr>
<tr>
<td>BMI</td>
</tr>
<tr>
<td>Oral corticosteroids</td>
</tr>
<tr>
<td>Rescue medication (short-acting β2 agonist)</td>
</tr>
<tr>
<td>Total serum IgE</td>
</tr>
<tr>
<td>Asthma control (GEMA criteria)</td>
</tr>
<tr>
<td>Skin prick tests</td>
</tr>
</tbody>
</table>

Abbreviations: BMI, body mass index; GEMA, Spanish Guideline on the Management of Asthma; ICU, intensive care unit.
*Allergic rhinitis, nasal polyps, chronic sinusitis, and atopic dermatitis.
analysis is described in Supplementary Table 1, and cluster demographics and clinical characteristics are presented in Supplementary Table 4. A correlation analysis was carried out to analyze the response to treatment among the main clusters and specific posttreatment parameters. The parameters included were severity, improvement in asthma control, decrease in exacerbations, use of health care resources, and background treatment (rescue medication and inhaled and oral corticosteroids [OCS]). Given the low number of patients, clusters C3 and C4 were not considered for further analysis. Supplementary Tables 5 and 6 show the comparison for C1 and C2 and summarize the results of the multivariate analysis.

We found 2 distinct and predominant severe asthma phenotypes in patients who responded fully to omalizumab, as clusters C1 and C2 accounted for 92% of the patients. C1 reflected a less allergic phenotype, namely, middle-aged patients (median, 55 years) who were overweight (median body mass index [BMI], 29) and mainly female (75.2%), with reduced lung function (forced expiratory volume in 1 second [FEV1] ≤80%, 86.5%). Patients were highly symptomatic with more clinically significant exacerbations (median, 3.0), although they did not require hospital admission; 74.5% of patients required OCS. The C2 phenotype comprised younger patients (median age, 40.5 years) with a slight female predominance (56.3%), normal weight (median BMI, 23.6), and better pulmonary function (FEV1 ≥80%, 42.7%). Patients were less symptomatic and experienced clinically significant exacerbations (median, 2.0), with a high percentage of atopy (46.9%) and high total IgE levels (median, 397.5 IU/mL). OCS was necessary in 45.8%.

As a whole, patients’ characteristics for both phenotypes, including age, BMI, smoking status, sex, FEV1, number of comorbidities, IgE levels, and the annual rate of severe asthma exacerbations, were very similar to those reported in previous studies, thus reinforcing the validity of the C1 and C2 clusters in the real-world clinical setting [5,7,11,12]. No differences were found between C1 and C2 for values of biomarkers such as eosinophils or fractional exhaled nitric oxide.

The study patients were selected because they were hyperresponders after treatment with omalizumab, ie, they achieved complete control of their asthma. Recently, there has been a focus on remission of asthma [13,14]. Menzes-Gow et al [14] defined remission as (1) sustained absence of significant asthma symptoms based on a validated instrument, (2) optimization and stabilization of lung function, and (3) no use of systemic corticosteroids to treat exacerbations or control long-term disease. The patients we report fulfilled these criteria after 1 year of treatment with omalizumab, although a longer-term follow-up is needed. Interestingly, the XPORT study population, in which no exacerbations were observed in 47.7% of patients 1 year after discontinuation of omalizumab, comprised mainly obese female asthmatics with poor lung function [15].

In conclusion, after unbiased cluster analyses, we found 2 specific types of responder. One was a middle-aged obese woman with poor lung function, who was highly symptomatic and dependent on corticosteroids. She was not necessarily allergic and had had many exacerbations. The other was an allergic nonobese asthmatic patient with many exacerbations but better lung function and lower dependence on corticosteroids. Prospective studies should be performed to determine whether these phenotypes are particularly responsive to omalizumab.

Acknowledgments

This study was sponsored by Novartis Farmacéutica SA, Spain and performed in accordance with principles of ICH for Good Clinical Practice (GCP). We would like to thank the following contributors to this work: Ada Luz Andreu Rodríguez, Adalberto Pacheco Galván, Adolfo Baloira Villar, Aizea Mardones Charraold, Alberto Levy Nahon, Alicia Padilla Galo, Ana Gómez-Bastero Fernández, Ana Montoro de Francisco, Ángel Blasco Sarramian, Ángel Ferrer Torres, Antonio León Jiménez, Antonio Moreno Fernández, Antonio Pablo Arenas Vacas, Astrid Crespo Lessmann, Beatriz Huertas Barbudo, Beatriz Rodríguez Jiménez, Carlos Martínez Rivera, Carlos Sanjuans Benito, Celia Pinedo Sierra, Consuelo Fernández Rodríguez, Enrique Macías Fernández, Eva Martínez Moragón, Fernando Ruiz Mori, Francisco Javier Guerra, Gemma Jorro Martínez, Gerardo Pérez Chica, Héctor Manuel González Expósito, Irene de Lorenzo García, Isabel Flores Martín, Isabel Molero Sancho, Jacinto Ramos González, Joan Serra Batlles, Joaquín Quiralt Enriquez, José Ángel Carretero, José Antonio Gullón Blanco, José Carlos Orta Cuevas, José Fernando Florido López, Juan Guallar Ballester, Lucía Gimeno Casanova, Luis Carazo Fernández, Luis Mateos Caballero, María José Torres Jaén, Marina Blanco Aparicio, Manuel Agustín Sojo González, Manuel García Marron, Mar Mosteiro Añón, María Ángeles Peña, María Jesús Rodríguez Nieto, María Purificación Jiménez, Marta Reche Frutos, Mercedes Cimarra Alvarez, Miguel Angel Diaz Palacios, Miguel Angel Tejedor Alonso, Patricia Mata Calderón, Pedro Cabrera-Navarro, Pilar Cebollero Rivas, Pilar Serrano Delgado, Rafael Llatser Oliva, Ramón Rodríguez Pacheco, Rosa Irigay Canals, Ruperto González Pérez, Sandra Dorado Arenas, Sheila Cabrejos Perotti, Teodoro Montemayor Rubio, Vanesa Vicens Zygmunt, and Anna Lladonosa Montull.

The authors were aided in the preparation of the manuscript by Ernesto Estefanía (Pivotal) and Aakash Katdare and Rabi Panigrah (Novartis).

Funding

The study was funded by Novartis Farmaceutica S.A., in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).

Conflicts of Interest

Dr Dávila reports nonfinancial support from Novartis during the conduct of the study, as well as personal fees from Novartis, Sanofi, GSK, AstraZeneca, LETI, ALK, Stallergènes, Dieter, Chiesi, and ImmunoTek and grants and personal fees from Thermo Fisher outside the submitted work.

Dr Campo reports personal fees from Novartis during the conduct of the study.

Dr Cimbollek reports nonfinancial support from Novartis Farmacéutica during the conduct of the study, as well as personal fees from AstraZeneca, GSK, Chiesi, Novartis,
Sanofi, TEVA, LETI, Diater, Thermo Fisher Diagnostics, and ALK outside the submitted work.

During 2017-2020, Dr. Almonacid received grants and participated in speaking activities and advisory boards and received consultancy fees from AstraZeneca, Boehringer-Ingelheim, Chiesi, GSK, ALK Mundipharma, Novartis, Pfizer, SEPAR, and NEUMOMADRID. Dr. Almonacid declares that he has not received, directly or indirectly, funding from the tobacco industry or its affiliates.

Dr. Quirce reports personal fees and nonfinancial support from GSK, AstraZeneca, Sanofi, Novartis, Mundipharma, Teva, and Allergy Therapeutics outside the submitted work.

Dr. Moreira reports personal fees from Novartis Farmacéutica, SA outside the submitted work.

Andreina Ramirez reports personal fees from Novartis Farmacéutica, SA outside the submitted work.

Dr. Soto-Campos reports nonfinancial support from Novartis during the conduct of the study, as well as personal fees from AstraZeneca, Boehringer, Novartis, GSK, Chiesi, Bial, and Menarini outside the submitted work.

References


Manuscript received March 18, 2021; accepted for publication July 5, 2021.

Paloma Campo
Allergy Unit
IBIMA-Regional University Hospital of Málaga, 29009 Málaga, Spain
E-mail: campomozo@gmail.com